For citations:

Dyakov I.N. Comparative clinical and economic evaluation of polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisolone (R-CHP) in the 1^st line therapy for adult patients with diffuse large B-cell lymphoma. Oncohematology. 2023;18(1):76-87. (In Russ.) https://doi.org/10.17650/1818-8346-2023-18-1-76-87